Tin tức & Cập nhật

A study conducted by researchers from Singapore demonstrates a protective effect of metformin against glaucoma in patients with diabetes.

Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.